Alfredo Niro1, Sabino Strippoli2, Giovanni Alessio3, Luigi Sborgia3, Nicola Recchimurzo3, Michele Guida2. 1. Eye Clinic, University of Bari "Aldo Moro", Bari, Italy. Electronic address: alfred.nir@tiscali.it. 2. Department of Medical Oncology, National Cancer Research Centre "Giovanni Paolo II", Bari, Italy. 3. Eye Clinic, University of Bari "Aldo Moro", Bari, Italy.
Abstract
PURPOSE: To report the clinical features and management of mitogen-activated protein kinase kinase inhibitor-associated ocular side effects in 4 patients with advanced melanoma and a review of literature. DESIGN: Interventional case series. METHODS: Four patients with advanced cutaneous melanoma were treated with a mitogen-activated protein kinase kinase (MEK) inhibitor as single therapy or together with a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor. All patients underwent ophthalmologic examinations at regular intervals or as needed, including visual acuity, intraocular pressure, external eye examination, and funduscopy. When pathologic findings were found, patients underwent visual field examination, optical coherence tomography (OCT), and/or fluorescein angiography. Ocular toxicity was assessed and handled according to the Common Terminology Criteria for Adverse Events. RESULTS: Ocular adverse events appeared early in the treatment. In 3 patients OCT revealed subfoveal neuroretinal elevation, often asymptomatic, also after discontinuation and re-starting of MEK inhibitor. Vascular injury appeared in 2 patients, in 1 case associated with a visual field defect reduced after discontinuation of the drug and use of systemic therapy. In 1 case an inflammatory reaction was observed in the anterior chamber. Visual symptoms were usually mild and short-lived. CONCLUSIONS: MEK inhibitor as a single agent or in combination with BRAF inhibitor induces transient retinopathy with time-dependent recurrence and usually mild visual symptoms. Vascular injuries can be observed and their management is essential in clinical practice. It is important to investigate all previous ocular disorders, systemic conditions, and pharmacologic interactions of MEK inhibitor that could facilitate the onset of associated ocular effects.
PURPOSE: To report the clinical features and management of mitogen-activated protein kinase kinase inhibitor-associated ocular side effects in 4 patients with advanced melanoma and a review of literature. DESIGN: Interventional case series. METHODS: Four patients with advanced cutaneous melanoma were treated with a mitogen-activated protein kinase kinase (MEK) inhibitor as single therapy or together with a v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor. All patients underwent ophthalmologic examinations at regular intervals or as needed, including visual acuity, intraocular pressure, external eye examination, and funduscopy. When pathologic findings were found, patients underwent visual field examination, optical coherence tomography (OCT), and/or fluorescein angiography. Ocular toxicity was assessed and handled according to the Common Terminology Criteria for Adverse Events. RESULTS: Ocular adverse events appeared early in the treatment. In 3 patients OCT revealed subfoveal neuroretinal elevation, often asymptomatic, also after discontinuation and re-starting of MEK inhibitor. Vascular injury appeared in 2 patients, in 1 case associated with a visual field defect reduced after discontinuation of the drug and use of systemic therapy. In 1 case an inflammatory reaction was observed in the anterior chamber. Visual symptoms were usually mild and short-lived. CONCLUSIONS:MEK inhibitor as a single agent or in combination with BRAF inhibitor induces transient retinopathy with time-dependent recurrence and usually mild visual symptoms. Vascular injuries can be observed and their management is essential in clinical practice. It is important to investigate all previous ocular disorders, systemic conditions, and pharmacologic interactions of MEK inhibitor that could facilitate the onset of associated ocular effects.
Authors: Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti Journal: Ophthalmology Date: 2017-07-12 Impact factor: 12.079
Authors: Akosua A Nti; Leona W Serrano; Harpal S Sandhu; Katherine E Uyhazi; Ilaina D Edelstein; Elaine J Zhou; Scott Bowman; Delu Song; Tara C Gangadhar; Lynn M Schuchter; Sheryl Mitnick; Alexander Huang; Charles W Nichols; Ravi K Amaravadi; Benjamin J Kim; Tomas S Aleman Journal: Retina Date: 2019-03 Impact factor: 4.256
Authors: Aswin Pyakurel; Delphine Balmer; Marc K Saba-El-Leil; Caroline Kizilyaprak; Jean Daraspe; Bruno M Humbel; Laure Voisin; Yun Z Le; Johannes von Lintig; Sylvain Meloche; Raphaël Roduit Journal: Mol Cell Biol Date: 2017-11-28 Impact factor: 4.272
Authors: Arthur E Frankel; Ugur Eskiocak; Jennifer G Gill; Stacy Yuan; Vijayashree Ramesh; Thomas W Froehlich; Chul Ahn; Sean J Morrison Journal: Neoplasia Date: 2017-03-06 Impact factor: 5.715